Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized phase 3 study of two doses of ALIMTA in previously platinum-treated advanced NSCLC
2004-000815-25Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of pemetrexed in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Overall survival time. Started Feb 2005; status: completed.
02
Drugs
pemetrexed
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2004-000815-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000815-25.